Trial
NCT03174522
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Ixaka Ltd
Collaborators
Andalusian Network for Design and Translation of Advanced Therapies
Condition
Peripheral Arterial Disease (PAD)
Intervention
REX-001
Why stopped
Independent Data Monitoring Committee recommendation to stop due to futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-16